Patents by Inventor Joseph R. Bertino

Joseph R. Bertino has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210299270
    Abstract: The present invention relates to anti-matriptase antibodies and immunoconjugates of anti-matriptase antibodies with cytotoxic agents and the use thereof for killing or inhibiting the growth of matriptase-expressing cancer cells, such as those of multiple myeloma and breast cancers. In particular, immunoconjugates comprising an anti-matriptase monoclonal antibody and anticancer agents such as auristatin, including monomethyl auristatin E (MMAE) and monomethyl auristatin F (MMAF) are introduced, which have potent antitumor activity in vivo. Moreover, importantly; there was no weight loss or other evidence of toxicity in the animals, indicating that no significant free drug was released into the circulation from the conjugate. The present invention also provides compositions comprising these new immunoconjugates and use of them for treatment of malignancies comprising cells that express matriptase.
    Type: Application
    Filed: March 12, 2021
    Publication date: September 30, 2021
    Applicants: Rutgers, The State University of New Jersey, Georgetown University
    Inventors: Siang-Yo Lin, Joseph R. Bertino, Chen-Yong Lin, Zoltan Szekely
  • Publication number: 20210177985
    Abstract: The present invention relates to matriptase antibodies and immunoconjugates of matriptase antibodies with cytotoxic agents and the use thereof for killing or inhibiting the growth of matriptase-expressing cancer cells, such as those of multiple myeloma and breast cancers. In particular, immunoconjugates comprising a matriptase monoclonal antibody and anticancer agents such as auristatin, including monomethyl auristatin E (MMAE) and monomethyl auristatin F (MMAF) are introduced, which have potent antitumor activity in vivo. Moreover, importantly; there was no weight loss or other evidence of toxicity in the animals, indicating that no significant free drug was released into the circulation from the conjugate. The present invention also provides compositions comprising these new immunoconjugates and use of them for treatment of malignancies comprising cells that express matriptase.
    Type: Application
    Filed: February 24, 2021
    Publication date: June 17, 2021
    Applicants: Rutgers, The State University of New Jersey, Georgetown University
    Inventors: Siang-Yo Lin, Joseph R. Bertino, Chen-Yong Lin
  • Publication number: 20200333235
    Abstract: This disclosure provides methods and systems for classifying biological particles, e.g., blood cells, microbes, circulating tumor cells (CTCs). Using impedance flow cytometry, such as multi-frequency impedance cytometry, in conjunction with supervised machine learning, the disclosed methods and systems demonstrated improved accuracy in classifying biological particles.
    Type: Application
    Filed: April 17, 2020
    Publication date: October 22, 2020
    Applicant: Rutgers, The State University of New Jersey
    Inventors: Mehdi Javanmard, Karan Ahuja, Jianye Sui, Joseph R. Bertino
  • Publication number: 20190358340
    Abstract: The present invention relates to matriptase antibodies and immunoconjugates of matriptase antibodies with cytotoxic agents and the use thereof for killing or inhibiting the growth of matriptase-expressing cancer cells, such as those of multiple myeloma and breast cancers. In particular, immunoconjugates comprising a matriptase monoclonal antibody and anticancer agents such as auristatin, including monomethyl auristatin E (MMAE) and monomethyl auristatin F (MMAF) are introduced, which have potent antitumor activity in vivo. Moreover, importantly; there was no weight loss or other evidence of toxicity in the animals, indicating that no significant free drug was released into the circulation from the conjugate. The present invention also provides compositions comprising these new immunoconjugates and use of them for treatment of malignancies comprising cells that express matriptase.
    Type: Application
    Filed: August 8, 2019
    Publication date: November 28, 2019
    Inventors: Siang-Yo Lin, Joseph R. Bertino, Chen-Yong Lin
  • Patent number: 10376597
    Abstract: The present invention relates to matriptase antibodies and immunoconjugates of matriptase antibodies with cytotoxic agents and the use thereof for killing or inhibiting the growth of matriptase-expressing cancer cells, such as those of multiple myeloma and breast cancers. In particular, immunoconjugates comprising a matriptase monoclonal antibody and anticancer agents such as auristatin, including monomethyl auristatin E (MMAE) and monomethyl auristatin F (MMAF) are introduced, which have potent antitumor activity in vivo. Moreover, importantly; there was no weight loss or other evidence of toxicity in the animals, indicating that no significant free drug was released into the circulation from the conjugate. The present invention also provides compositions comprising these new immunoconjugates and use of them for treatment of malignancies comprising cells that express matriptase.
    Type: Grant
    Filed: December 1, 2017
    Date of Patent: August 13, 2019
    Assignees: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY, GEORGETOWN UNIVERSITY
    Inventors: Siang-Yo Lin, Joseph R. Bertino, Chen-Yong Lin
  • Publication number: 20190151464
    Abstract: The present invention relates to anti-matriptase antibodies and immunoconjugates of anti-matriptase antibodies with cytotoxic agents and the use thereof for killing or inhibiting the growth of matriptase-expressing cancer cells, such as those of multiple myeloma and breast cancers. In particular, immunoconjugates comprising an anti-matriptase monoclonal antibody and anticancer agents such as auristatin, including monomethyl auristatin E (MMAE) and monomethyl auristatin F (MMAF) are introduced, which have potent antitumor activity in vivo. Moreover, importantly; there was no weight loss or other evidence of toxicity in the animals, indicating that no significant free drug was released into the circulation from the conjugate. The present invention also provides compositions comprising these new immunoconjugates and use of them for treatment of malignancies comprising cells that express matriptase.
    Type: Application
    Filed: March 17, 2017
    Publication date: May 23, 2019
    Inventors: Siang-Yo Lin, Joseph R. Bertino, Chen-Yong Lin, Zoltan Szekely
  • Publication number: 20180177889
    Abstract: The present invention relates to matriptase antibodies and immunoconjugates of matriptase antibodies with cytotoxic agents and the use thereof for killing or inhibiting the growth of matriptase-expressing cancer cells, such as those of multiple myeloma and breast cancers. In particular, immunoconjugates comprising a matriptase monoclonal antibody and anticancer agents such as auristatin, including monomethyl auristatin E (MMAE) and monomethyl auristatin F (MMAF) are introduced, which have potent antitumor activity in vivo. Moreover, importantly; there was no weight loss or other evidence of toxicity in the animals, indicating that no significant free drug was released into the circulation from the conjugate. The present invention also provides compositions comprising these new immunoconjugates and use of them for treatment of malignancies comprising cells that express matriptase.
    Type: Application
    Filed: December 1, 2017
    Publication date: June 28, 2018
    Inventors: Siang-Yo Lin, Joseph R. Bertino, Chen-Yong Lin
  • Patent number: 9849192
    Abstract: The present invention relates to matriptase antibodies and immunoconjugates of matriptase antibodies with cytotoxic agents and the use thereof for killing or inhibiting the growth of matriptase-expressing cancer cells, such as those of multiple myeloma and breast cancers. In particular, immunoconjugates comprising a matriptase monoclonal antibody and anticancer agents such as auristatin, including monomethyl auristatin E(MMAE) and monomethyl auristatin F(MMAF) are introduced, which have potent antitumor activity in vivo. Moreover, importantly; there was no weight loss or other evidence of toxicity in the animals, indicating that no significant free drug was released into the circulation from the conjugate. The present invention also provides compositions comprising these new immunoconjugates and use of them for treatment of malignancies comprising cells that express matriptase.
    Type: Grant
    Filed: March 18, 2016
    Date of Patent: December 26, 2017
    Assignees: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY, GEORGETOWN UNIVERSITY
    Inventors: Siang-Yo Lin, Joseph R. Bertino, Chen-Yong Lin
  • Patent number: 9682094
    Abstract: The present invention relates to matriptase antibodies and immunoconjugates of matriptase antibodies with cytotoxic agents and the use thereof for killing or inhibiting the growth of matriptase-expressing cancer cells, such as those of multiple myeloma and breast cancers. In particular, immunoconjugates comprising a matriptase monoclonal antibody and anticancer agents such as doxorubicin (DOX) are introduced, which are equipotent to anticancer agents used in free form but exhibit significantly reduced cardiotoxicity and almost no adverse effects on normal bone marrow-derived mesenchymal stromal cells that do not express matriptase. The present invention also provides compositions comprising these new immunoconjugates and use of them for treatment of malignancies comprising cells that express matriptase.
    Type: Grant
    Filed: August 26, 2015
    Date of Patent: June 20, 2017
    Assignees: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY, GEORGETOWN UNIVERSITY
    Inventors: Siang-Yo Lin, Joseph R. Bertino, Chen-Yong Lin
  • Patent number: 9549993
    Abstract: Disclosed are antibody drug conjugates (ADC) that include highly potent toxic agents with specific antibodies to target tumors. Also disclosed are related antibodies, polypeptides, nucleic acids, host cells, compositions, and uses.
    Type: Grant
    Filed: October 2, 2013
    Date of Patent: January 24, 2017
    Assignees: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY, GEORGETOWN UNIVERSITY
    Inventors: Siang-Yo Lin, Joseph R. Bertino, Chen-Yong Lin, Michael Johnson
  • Publication number: 20160263244
    Abstract: The present invention relates to matriptase antibodies and immunoconjugates of matriptase antibodies with cytotoxic agents and the use thereof for killing or inhibiting the growth of matriptase-expressing cancer cells, such as those of multiple myeloma and breast cancers. In particular, immunoconjugates comprising a matriptase monoclonal antibody and anticancer agents such as auristatin, including monomethyl auristatin E (MMAE) and monomethyl auristatin F (MMAF) are introduced, which have potent antitumor activity in vivo. Moreover, importantly; there was no weight loss or other evidence of toxicity in the animals, indicating that no significant free drug was released into the circulation from the conjugate. The present invention also provides compositions comprising these new immunoconjugates and use of them for treatment of malignancies comprising cells that express matriptase.
    Type: Application
    Filed: March 18, 2016
    Publication date: September 15, 2016
    Inventors: Siang-Yo Lin, Joseph R. Bertino, Chen-Yong Lin
  • Patent number: 9314497
    Abstract: The instant invention provides amino acid sequences competing with E2F for DNA binding. Methods of using said amino acid sequences for treatment of hormone-refractory prostate cancer are also provided.
    Type: Grant
    Filed: September 2, 2014
    Date of Patent: April 19, 2016
    Assignee: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
    Inventors: Joseph R. Bertino, Debabrata Banerjee, Tamara Minko, Olga B. Garbuzenko, Xiaoqi Xie, John E. Kerrigan, Emine E. Abali, Kathleen W. Scotto
  • Publication number: 20160015728
    Abstract: The present invention relates to matriptase antibodies and immunoconjugates of matriptase antibodies with cytotoxic agents and the use thereof for killing or inhibiting the growth of matriptase-expressing cancer cells, such as those of multiple myeloma and breast cancers. In particular, immunoconjugates comprising a matriptase monoclonal antibody and anticancer agents such as doxorubicin (DOX) are introduced, which are equipotent to anticancer agents used in free form but exhibit significantly reduced cardiotoxicity and almost no adverse effects on normal bone marrow-derived mesenchymal stromal cells that do not express matriptase. The present invention also provides compositions comprising these new immunoconjugates and use of them for treatment of malignancies comprising cells that express matriptase.
    Type: Application
    Filed: August 26, 2015
    Publication date: January 21, 2016
    Inventors: Siang-Yo Lin, Joseph R. Bertino, Chen-Yong Lin
  • Publication number: 20150250895
    Abstract: Disclosed are antibody drug conjugates (ADC) that include highly potent toxic agents with specific antibodies to target tumors. Also disclosed are related antibodies, polypeptides, nucleic acids, host cells, compositions, and uses.
    Type: Application
    Filed: October 2, 2013
    Publication date: September 10, 2015
    Applicant: Georgetown University
    Inventors: Siang-Yo Lin, Joseph R. Bertino, Chen-Yong Lin, Michael Johnson
  • Publication number: 20150202248
    Abstract: The instant invention provides amino acid sequences competing with E2F for DNA binding. Methods of using said amino acid sequences for treatment of hormone-refractory prostate cancer are also provided.
    Type: Application
    Filed: September 2, 2014
    Publication date: July 23, 2015
    Inventors: Joseph R. Bertino, Debabrata Banerjee, Tamara Minko, Olga B. Garbuzenko, Xiaoqi Xie, John E. Kerrigan, Emine E. Abali, Kathleen W. Scotto
  • Patent number: 8822421
    Abstract: The instant invention provides amino acid sequences competing with E2F for DNA binding. Methods of using said amino acid sequences for treatment of hormone-refractory prostate cancer are also provided.
    Type: Grant
    Filed: October 14, 2011
    Date of Patent: September 2, 2014
    Assignee: Rutgers, The State University of New Jersey
    Inventors: Joseph R. Bertino, Debabrata Banerjee, Tamara Minko, Olga B. Garbuzenko, Xiaoqi Xie, John E. Kerrigan, Emine E. Abali, Kathleen W. Scotto
  • Publication number: 20120294800
    Abstract: The present invention relates to matriptase antibodies and immunoconjugates of matriptase antibodies with cytotoxic agents and the use thereof for killing or inhibiting the growth of matriptase-expressing cancer cells, such as those of multiple myeloma and breast cancers. In particular, immunoconjugates comprising a matriptase monoclonal antibody and anticancer agents such as doxorubicin (DOX) are introduced, which are equipotent to anticancer agents used in free form but exhibit significantly reduced cardiotoxicity and almost no adverse effects on normal bone marrow-derived mesenchymal stromal cells that do not express matriptase. The present invention also provides compositions comprising these new immunoconjugates and use of them for treatment of malignancies comprising cells that express matriptase.
    Type: Application
    Filed: November 18, 2010
    Publication date: November 22, 2012
    Applicant: UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY
    Inventors: Siang-Yo Lin, Joseph R. Bertino, Chen-Yong Lin
  • Publication number: 20120093919
    Abstract: The instant invention provides amino acid sequences competing with E2F for DNA binding. Methods of using said amino acid sequences for treatment of hormone-refractory prostate cancer are also provided.
    Type: Application
    Filed: October 14, 2011
    Publication date: April 19, 2012
    Applicants: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY, UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY
    Inventors: Joseph R. Bertino, Debabrata Banerjee, Tamara Minko, Olga B. Garbuzenko, Xiaoqi Xie, John E. Kerrigan, Emine E. Abali, Kathleen W. Scotto
  • Publication number: 20110020291
    Abstract: Cells, compositions, and methods of cell therapy for administering a therapeutically effective amount of stem cells or cell concentrate to achieve accelerated wound healing of normal and chronic wounds, while minimizing the formation of scar tissue.
    Type: Application
    Filed: November 15, 2008
    Publication date: January 27, 2011
    Inventors: Debrabrata Banerjee, Prasun J. Mishra, Pravin J. Mishra, Joseph R. Bertino, Rita Humeniuk, John Glod
  • Publication number: 20100151004
    Abstract: Methods for the treatment of disorders, including cancer, are described which include administering to a subject a DNA methylation inhibitor and an antineoplastic agent. Compositions containing a DNA methylation inhibitor and an antineoplastic agent, which are useful in treating disorders including cancer, are also described. Additionally, methods useful for developing a prognosis for or diagnosing a subject's development of resistance to treatment with a chemotherapeutic agent are described.
    Type: Application
    Filed: March 7, 2008
    Publication date: June 17, 2010
    Applicant: UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY
    Inventors: Debabrata Banerjee, Joseph R. Bertino, Rita Humeniuk, Prasun J. Mishra